| Nov 19 |
Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
|
| Nov 18 |
Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
|
| Nov 15 |
What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday?
|
| Nov 15 |
Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
|
| Nov 5 |
Vir Biotechnology's Refocused Pipeline: Hepatitis And Oncology Could Still Pay Off
|
| Nov 2 |
Vir Biotechnology Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 1 |
Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ...
|
| Nov 1 |
Vir Biotechnology Q3 2024 Earnings Preview
|
| Nov 1 |
Vir Biotechnology (NASDAQ:VIR) shareholders have endured a 76% loss from investing in the stock three years ago
|
| Nov 1 |
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners
|
